Research programme: colony stimulating factor 1 receptor antagonists - Daiichi Sankyo
Alternative Names: AC710Latest Information Update: 22 Feb 2023
At a glance
- Originator Ambit Biosciences Corporation
 - Developer Daiichi Sankyo Company
 - Class Small molecules
 - Mechanism of Action Macrophage colony-stimulating factor receptor antagonists
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 - Available For Licensing Yes
 
Highest Development Phases
- Discontinued Cancer; Inflammation
 
Most Recent Events
- 22 Feb 2023 Discontinued - Preclinical for Cancer in USA (unspecified route)
 - 22 Feb 2023 Discontinued - Preclinical for Inflammation in USA (unspecified route)
 - 28 May 2018 No recent reports of development identified for preclinical development in Cancer in USA